Comparison of the effect of miconazole and clotrimazole in the treatment of vulvovaginal candidiasis among women seen in a tertiary medical center from 2016 to 2020 /
Shiara Marriz Marquez; Lylah Reyes.
- Fairview, Quezon City: Department of Obstetrics and Gynecology, FEU-NRMF, 2021.
- 29 pages: tables; (in folder) + with flash drive (soft copy).
Includes appendices and bibliographical references.
Abstract: Vulvovaginal candidiasis (VVC) is one of the frequent infections of the female genital tract and is the second most common cause of vaginal infections after bacterial vaginosis. According to the Center for Disease Control and Prevention (CDC), azoles are the first-line of treatment for VVC. Among the azoles available in the Philippines, only miconazole and clotrimazole are recommended for both pregnant and non-pregnant women. This study reviewed a total of 316 records of patients, regardless of pregnancy status who were given either single dose 1200 mg miconazole or a 6-day 100 mg clotrimazole vaginal suppository and treatment for vulvovaginal candidiasis. Upon follow-up, 11 out of 316 (3.46%) were still symptomatic which was noted in 2 (18.1%) from the miconazole group while 9 (81.8%) from the clotrimazole group. The difference for these outcome between the treatment groups is statistically significant. With regards to treatment failure rate, for miconazole it is 1.2% (2/161) while for clotrimazole, it is 5.8% (9/155). None of the charts of these women had recorded adverse reaction to the given treatment. In conclusion, the single-dose miconazole regimen has a significant higher clinical cure rate than the 6-day clotrimazole. It has the potential to improve patient compliance and improve treatment outcome at a lower cost.